Recent Discoveries of Diagnostic, Prognostic and Predictive Biomarkers for Pancreatic Cancer

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease with a dismal prognosis that is frequently diagnosed at an advanced stage. Although less common than other malignant diseases, it currently ranks as the fourth most common cause of cancer-related death in the European Union with a five...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2020-11, Vol.12 (11), p.3234
Main Authors: Khomiak, Andrii, Brunner, Marius, Kordes, Maximilian, Lindblad, Stina, Miksch, Rainer Christoph, Öhlund, Daniel, Regel, Ivonne
Format: Article
Language:English
Subjects:
Biological markers
Diagnosis
DNA biomarkers
Identification and classification
immune biomarkers
metabolome biomarkers
microbiome biomarkers
Pancreatic cancer
pancreatic ductal adenocarcinoma
Prognosis
protein biomarkers
Review
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease with a dismal prognosis that is frequently diagnosed at an advanced stage. Although less common than other malignant diseases, it currently ranks as the fourth most common cause of cancer-related death in the European Union with a five-year survival rate of below 9%. Surgical resection, followed by adjuvant chemotherapy, remains the only potentially curative treatment but only a minority of patients is diagnosed with locally resectable, non-metastatic disease. Patients with advanced disease are treated with chemotherapy but high rates of treatment resistance and unfavorable side-effect profiles of some of the used regimens remain major challenges. Biomarkers reflect pathophysiological or physiological processes linked to a disease and can be used as diagnostic, prognostic and predictive tools. Thus, accurate biomarkers can allow for better patient stratification and guide therapy choices. Currently, the only broadly used biomarker for PDAC, CA 19-9, has multiple limitations and the need for novel biomarkers is urgent. In this review, we highlight the current situation, recent discoveries and developments in the field of biomarkers of PDAC and their potential clinical applications.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers12113234